Pliant Therapeutics has scrapped its Phase IIb Beacon-IPF trial for bexotegrast in idiopathic pulmonary fibrosis (IPF), after ...

Pliant Therapeutics (NASDAQ:PLRX – Free Report) had its price objective lowered by Citigroup from $4.00 to $1.50 in a report ...

Pliant Therapeutics (NASDAQ:PLRX – Get Free Report) was downgraded by equities research analysts at Stifel Nicolaus from a “buy” rating to a “hold” rating in a research note issued on Monday, ...

Robert Lenz is leaving the brain drug developer to “pursue other interests.” Elsewhere, Acelyrin rejected a bid by Concentra and Atara cut staff.

Whenever President Trump talks about Ukraine there is always something off, something missing, that makes you wonder what he ...

Fintel reports that on March 4, 2025, Needham downgraded their outlook for Pliant Therapeutics (NasdaqGS:PLRX) from Buy to ...

Fintel reports that on March 3, 2025, Leerink Partners downgraded their outlook for Pliant Therapeutics (NasdaqGS:PLRX) from ...

Pliant Therapeutics ends its Phase 2b IPF trial for bexotegrast, prompting a Needham downgrade to Hold due to limited ...

Citi lowered the firm’s price target on Pliant Therapeutics (PLRX) to $1.50 from $4 and keeps a Neutral rating on the shares. The company ...

Discontinuation of BEACON-IPF following DSMB and outside expert panel recommendationSOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE ...

Getting rid of the military’s top lawyers is not exactly a sign that the Trump administration wants to follow the law.

Pliant Therapeutics discontinued its BEACON-IPF trial for bexotegrast due to safety concerns but observed early efficacy. The ...